XML 90 R61.htm IDEA: XBRL DOCUMENT
v3.24.1

Revenues from Contracts with Customers - Additional Information (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | € 3,819.0 | € 17,310.6 | € 18,976.7
Contract liabilities | 751.8 | 125.5 |
Remaining upfront fees contract liabilities |  | 65.7 |
Advance payment received for future COVID 19 vaccine sale |  | 56.3 |
Commercial revenues |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 3,815.5 | 17,194.6 | 18,874.0
United States |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 3,010.9 | 12,709.7 | 14,636.5
Germany |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 482.7 | 3,031.0 | 2,241.9
Belgium |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues |  |  | 675.0
Pfizer Inc. |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 3,293.0 | 13,795.8 | 15,500.0
German Federal Ministry of Health |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 473.6 | 3,020.5 | 1,945.6
Contract liabilities | 302.3 |  |
Sales to collaboration partners | Commercial revenues |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 275.3 | 1,224.3 | 970.9
Sales to collaboration partners | Commercial revenues | Manufacturing Variances |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 74.5 | 850.0 | 31.0
Direct product sales to customers | Commercial revenues |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues | 473.6 | € 3,184.7 | 3,007.2
Share of collaboration partners' sales milestones | Commercial revenues |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Total revenues |  |  | € 476.6
Pfizer (COVID-19 vaccine) |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Contract liabilities | 386.4 |  |
Pfizer (Zoster) |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |
Remaining upfront fees contract liabilities | € 62.3 |  |

X
- Definition Advance Payment Received For Future COVID-19 Vaccine Sale + References No definition available. + Details
Name: | bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale
Namespace Prefix: | bntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Remaining Upfront Fees Contract Liabilities + References No definition available. + Details
Name: | bntx_RemainingUpfrontFeesContractLiabilities
Namespace Prefix: | bntx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 116 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bntx_CommercialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_DE
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BE
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_GermanFederalMinistryOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ManufacturingVariancesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineDirectProductSalesToCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_PfizerCOVID19VaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=bntx_PfizerZosterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |